Quality of Care for Non-ST-Segment Elevation Acute Coronary Syndromes: What Should Be the Status Quo?

Nearly 13 million people in the United States have coronary artery disease (CAD), and more than 750,000 deaths are attributed to this disease each year [1]. Although there have been substantial therapeutic advances in the treatment of CAD in the past decade, these new therapies and approaches to care are not being systematically applied across the health system. Guidelines developed by the American College of Cardiology/American Heart Association (ACC/AHA) promote the systematic application of an evidence-based approach to the management of patients with suspected acute coronary syndrome (ACS). Clinical practice guidelines written by expert panels synthesize research findings from randomized clinical trials and observational studies as well as consensus opinion. Such guidelines can be useful for the practitioner because they distill a large and potentially overwhelming body of research and knowledge into clinically practical and relevant approaches to care. Through explicit statements that a therapy is “useful and effective” (ie, a class I recommendation), guidelines provide one framework for defining quality medical care. Importantly, the practice of evidence-based medicine, facilitated by clinical practice guidelines, has been associated with better patient outcomes [2–4]. However, resistance to adoption of guidelines in daily medical practice remains. Guidelines may be construed by physicians as a threat to their autonomy by placing “cookbook” constraints on the art of medicine [5,6]. Agrowing body of scientific literature, including the Institute of Medicine’s (IOM) report Crossing the Quality Chasm [7], reports that deviations from evidence-based guideline recommendations are common in daily practice, particularly among sociodemographic subgroups of patients. As the following case study illustrates, these nationwide gaps in treatment always begin with an individual patient.

[1]  J. Ensign Quality of health care: the views of homeless youth. , 2004, Health services research.

[2]  Á. Avezum,et al.  Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. , 2004, The American journal of medicine.

[3]  W. Peacock Vein-to-brain Time: An Emergency Department Quality of Care Marker for Non-ST-segment Elevation Acute Coronary Syndromes , 2004 .

[4]  L. Newby,et al.  1154-90 Suboptimal treatment of patients with non-ST elevation acute coronary syndromes presenting with positive baseline troponin values , 2004 .

[5]  E. DeLong,et al.  838-4 National evaluation of long-term adherence to beta-blocker therapy after acute myocardial infarction in patients with commercial health insurance , 2004 .

[6]  K. Eagle,et al.  Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes , 2004, Circulation.

[7]  P. Crome What's different about older people. , 2003, Toxicology.

[8]  Laura P Coombs,et al.  Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. , 2003, JAMA.

[9]  J. Shepherd,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial , 2003 .

[10]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[11]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[12]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[13]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[14]  Alastair Baker,et al.  Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.

[15]  H. Krumholz,et al.  A qualitative study of increasing beta-blocker use after myocardial infarction: Why do some hospitals succeed? , 2001, JAMA.

[16]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[17]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[18]  J J Allison,et al.  Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial. , 2001, JAMA.

[19]  H. Krumholz,et al.  A Qualitative Study of Increasing β-Blocker Use After Myocardial Infarction: Why Do Some Hospitals Succeed? , 2001 .

[20]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .

[21]  M. Millenson Demanding medical excellence : doctors and accountability in the information age : with a new afterword , 1997 .

[22]  J. Gore,et al.  Sex differences in symptom presentation associated with acute myocardial infarction: a population-based perspective. , 1998, American heart journal.

[23]  M. Chassin,et al.  Quality of health care. Part 3: improving the quality of care. , 1996, The New England journal of medicine.

[24]  A. Donabedian,et al.  The quality of care. How can it be assessed? , 1988, JAMA.